Viewing stories from November, 2017

29 November 2017
AGM Chairman’s address and CEO presentation

Chairman’s address and the CEO’s presentation to the 2017 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Read More

21 November 2017
NDA submission for Starpharma’s VivaGel® BV

BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage.

Go to article
Read More

21 November 2017
NDA submission for VivaGel® BV in the US

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process. 

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.